On May 31, Johnson & Johnson finalized its $13.1 billion acquisition of Shockwave Medical, a cardiovascular medical device company.
Shockwave, which now operates under J&J's MedTech division, offers the market's only intravascular lithotripsy platform for coronary artery disease and peripheral disease, according to a J&J news release.
The company has been steadily growing its cardiovascular line after buying Abiomed in 2022 for $16.6 billion and Laminar in late 2023 for $400 million. The latest acquisition has propelled J&J to be a "leader in four of the largest and highest-growth medtech markets within cardiovascular intervention," the release said.